Special Issue | 29 March 2013Cancer Genomics

INTRODUCTION—With the completion of the human genome in 2001, many researchers immediately set their sights on using this information to better understand the genetics and, more recently, epigenetic effects identified during the initiation, development, and progression of cancer. Moving from the pre-genome era identification of single gene variants associated with hereditary cancers, advances in sequencing technology have enabled the use of a whole-genome approach to examine the differences between the genomes of, and epigenetic regulation of, tumor and patient DNA. This issue of Science examines how these advances are shaping our current understanding of cancer at the genomic level. [Read the full introduction]

All of the articles in this special section are FREE with registration. Sign up today!

From Science

News Focus

Steering Cancer Genomics Into the Fast Lane

With her passion for DNA sequencing technology, Elaine Mardis now hopes to help cancer patients.
News Focus

The Downside of Diversity

Increasing genetic evidence that tumors contain a heterogeneous mix of cells may explain why cancer treatments often fail.
Review Free Access

Cancer Genome Landscapes

Cancer genome analyses have underscored the complexity of the disease and suggested new guiding principles for patient care.

Diagnostic Cancer Genome Sequencing and the Contribution of Germline Variants

Standards are needed to optimally utilize data obtained from sequencing cancer patients genomes.

Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed

Genetic variants of both the patient and tumor need to be taken into account in determining optimal cancer drug therapies.

Epigenetic Reprogramming in Cancer

Oncogenic transformation, tumor heterogeneity, and cancer stem cell models show parallel molecular mechanisms.

Grappling with Cancer

The complexity of cancer biology requires a systems dynamics view of the disease.

From Science Signaling

Science Signaling Editorial Guide

Focus Issue: From Genomic Mutations to Oncogenic Pathways

Understanding alterations in signaling networks is key to developing rational, personalized cancer therapies.
Science Signaling Perspective

Disrupting the Scaffold to Improve Focal Adhesion Kinase–Targeted Cancer Therapeutics

Targeting the scaffold of focal adhesion kinase is a therapeutic opportunity to inhibit signaling pathways selectively in cancer cells.
Science Signaling Perspective

A Wnt-er Migration: The Confusing Role of β-Catenin in Melanoma Metastasis

The repertoire of Wnt receptors and coreceptors in melanoma cells may determine whether β-catenin promotes metastasis.
Science Signaling Perspective

BIM, PUMA and the Achilles’ Heel of Oncogene Addiction

Drugs that target oncogenic receptor tyrosine kinases activate parallel signaling pathways that trigger cell death.
Science Signaling Research Article

PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis

Combining drugs that inhibit anti-apoptotic proteins with oncogenic kinase inhibitors may overcome drug resistance in cancer therapy.
Science Signaling Research Article

Dysregulated RasGRP1 Responds to Cytokine Receptor Input in T Cell Leukemogenesis

Understanding the signaling mechanisms that can lead to T cell leukemia may enable personalized therapies.
Science Signaling Research Resource

Kinase-Substrate Enrichment Analysis Provides Insights Into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells

Computational analysis of phosphoproteomics data predicts the sensitivity of leukemia cells to kinase inhibitors.
Science Signaling Perspective

The Scientific Drunk and the Lamp Post: Massive Sequencing Efforts in Cancer Discovery and Treatment

Signaling networks may provide greater return in the investment in cancer research.
Science Careers

Also in this Special Issue:

Related Resources

Science Translational Medicine Commentary

Science Special Issues

More Special Issues >>